Edition:
India

Roche Holding AG (RHHBY.PK)

RHHBY.PK on OTC Markets Group

41.73USD
1 Dec 2020
Change (% chg)

$0.00 (+0.00%)
Prev Close
$41.73
Open
$41.20
Day's High
$41.75
Day's Low
$41.20
Volume
3,101,945
Avg. Vol
1,097,856
52-wk High
$47.15
52-wk Low
$35.04

Select another date:

Thu, Oct 22 2020

Photo

Roche, Atea team up on potential COVID-19 pill

ZURICH Roche Holding and Atea Pharmaceuticals have joined forces to develop an antiviral oral treatment called AT-527, now in phase 2 clinical trials, as a potential treatment for COVID-19 patients, the companies said on Thursday.

Roche, Atea team up on potential COVID-19 pill

ZURICH, Oct 22 Roche Holding and Atea Pharmaceuticals have joined forces to develop an antiviral oral treatment called AT-527, now in phase 2 clinical trials, as a potential treatment for COVID-19 patients, the companies said on Thursday.

Roche, Blueprint lung cancer drug wins FDA approval

Roche Holding AG on Friday said a therapy it co-developed with Cambridge-based Blueprint Medicines Corp was approved by the U.S. health regulator for the treatment of patients with a type of non-small cell lung cancer (NSCLC).

Roche, Blueprint lung cancer drug wins FDA approval

Sept 4 Roche Holding AG on Friday said a therapy it co-developed with Cambridge-based Blueprint Medicines Corp was approved by the U.S. health regulator for the treatment of patients with a type of non-small cell lung cancer (NSCLC).

Roche-PTC Therapeutics' oral spinal muscular atrophy drug wins FDA approval

The U.S. Food and Drug Administration on Friday approved an oral treatment from Roche Holding AG and PTC Therapeutics Inc for spinal muscular atrophy in adults and children two months and above.

UPDATE 2-Roche-PTC Therapeutics' oral spinal muscular atrophy drug wins FDA approval

Aug 7 The U.S. Food and Drug Administration on Friday approved an oral treatment from Roche Holding AG and PTC Therapeutics Inc for spinal muscular atrophy in adults and children two months and above.

Roche's combo therapy for advanced breast cancer gets U.S. FDA approval

The U.S. Food and Drug Administration on Monday approved Roche Holding AG's combination therapy for a form of advanced breast cancer that has spread to other parts of the body.

Roche's combo therapy for advanced breast cancer gets U.S. FDA approval

The U.S. Food and Drug Administration on Monday approved Roche Holding AG's combination therapy for a form of advanced breast cancer that has spread to other parts of the body.

UPDATE 1-Roche's combo therapy for advanced breast cancer gets U.S. FDA approval

June 29 The U.S. Food and Drug Administration on Monday approved Roche Holding AG's combination therapy for a form of advanced breast cancer that has spread to other parts of the body.

Roche's combo therapy for advanced breast cancer gets U.S. FDA approval

June 29 The U.S. Food and Drug Administration on Monday approved Roche Holding AG's combination therapy for a form of advanced breast cancer that has spread to other parts of the body.

Select another date: